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Materials and methods: A prospective study was used to assess patients who underwent radiofre-
quency ablation for treatment of HCC nodules using MDCT. MDCT was done immediately after
procedure to asses treatment success, then after one month for decision making; either good ablation
or reablation for residual tumor if present. Three and six months follow up for detection of marginal
growth or newly developed HCC nodules. One year MDCT follow up for true technical success.
Results: MDCT ﬁndings were as follows: immediate evaluation showed good ablation in 29 patients
(96.7%), and one patient showed residual tumor tissue reablated at the same session. In one month
follow up nodular marginal enhancement denoting residual tumor was seen in 2 patients (6.7%). In
three months follow up no residual tumor or recurrence (100%); in six months follow up recurrence
was seen in one patient (3.4%) and another patient (3.4%) showed a new HCC focus. In one year
follow up marginal recurrence was seen in three patients (10%).
Conclusion: RF ablation is an internationally approved treatment for HCC. MDCT should be the
corner stone method for follow to achieve better results and improve the survival rate via early detec-
tion and immediate interference with any new or recurrent lesions.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Hepatocellular carcinoma is the most common primary malig-
nant liver tumor and one of the most common causes of cancer
mortality in the world. It usually arises on top of cirrhotic
liver. It has high incidence rate above 40 years with male to
female ratio about 8:1 with more than 90% mortality rate. It
410 N.F. El Ameen et al.is estimated that HCC is responsible for more than 600,000
deaths annually worldwide (1,2).
Tumor resection is the deﬁnitive treatment for HCC.
Unfortunately only 20% of patients are candidates for surgical
resection. Advanced liver cirrhosis or multicentricity makes
surgery impossible. Furthermore, recurrence is frequent even
after apparently curative resection (3).
In past decades a variety of minimally invasive therapies
have been used as an alternative to hepatic resection such as
trans-catheter arterial chemoembolization (TACE), ethanol
injection, cryosurgery, microwave ablation, laser photocoagu-
lation and radio-frequency (RF) ablation.(4–9) Among locore-
gional treatments for hepatocellular carcinoma (HCC),
radiofrequency ablation (RFA) has been accepted as the most
popular alternative to curative transplantation or resection,
and it shows an excellent local tumor control rate and accept-
able morbidity (10–13).
The fact that, HCC has a very rich arterial neovasculariza-
tion, makes it better detected in triphasic MDCT examination
during hepatic arterial dominant phase. This also makes
MDCT, the most accepted imaging modality for evaluation
of therapeutic response to RF ablation. It helps in makingFig. 1 (A) Small sized HCC with marginal enhancement. (B) Immed
zone, no residual tumor. (C) 3 months follow up showed good ablated
the size of the ablated lesion, no recurrence and no distant spread.decision whether the patient is completely cured or will be
amenable for treatment repetition (14–17).
2. Patient and methods
Thirty patients were studied in a prospective study conducted
between August 2010 and September 2011. They were pre-
sented at the radiology department, El-Minia University Hos-
pital. All of them underwent radiofrequency ablation for HCC
on top of liver cirrhosis after approval from the ethics commit-
tee of our institution and written consent from each patient
was obtained. Follow up MDCT examination was done for
all of them at 1, 3, 6 and 12 months interval.
2.1. Inclusion criteria for RF ablation
 Patients with HCC diagnosed by US as a hypo-echoic hepa-
tic lesion on top of cirrhotic liver with coarse parenchyma.
The lesion conﬁrmed by triphasic CT as intensely enhanced
lesion in the arterial phase. Alpha feto protein (AFP) was
done to all for conﬁrmation.
 Tumor size not greater than 5 cm.iate post RF showed good ablated lesion with marginal hyperemic
lesion, no recurrence. (D) 6 months follow up showed reduction in
Table 1 MDCT ﬁndings in 30 patients with HCC immedi-
ately after RF ablation.
CT ﬁndings Number
Hypo-attenuated coagulation zone 27 (90%)
Gas bubbles 24 (80%)
Marginal hyperemic zone 24 (80%)
Immediate complication 3 (10%)
Tumor residual 1 (3.3%)
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MDCT (Child Pugh class A or B).2.2. Exclusion criteria from the study
 Patients not amenable for RF ablation e.g. patients with PV
thrombosis, metastasis, severe coagulation disorders,
lesions larger than 5 cm and multi-centric tumors.2.3. Imaging protocol
1. Abdominal ultrasonography: Using logic pro General Elec-
tric machine with curved array transducer, and frequency
ranging from 3.5 to 11 MHz. Any focal lesion detectedFig. 2 (A) Medium sized HCC post RF ablation with good ablated c
up showed local marginal recurrence presented as intensely enhanced m
second RF ablation session with complete ablation.was evaluated as regards site, size, characteristics and any
associated pathyology e.g. portal vein thrombosis or asci-
tes. Any solid lesion on top of cirrhosis was considered to
be malignant and sent for MDCT and AFP.
2. Abdominal MDCT: Using 16-detector MDCT scanner
(Bright Speed 16; GE Medical Systems) after oral abdomi-
nal preparation. Contrast material was injected with a
power injector (Medrad, Stellate) through an 18–20 gauge
catheter into the antecubital vein. The injection rate was
4 mL/s. A total of 90 mL of nonionic contrast material
was used. Imaging protocol was: Arterial phase at (30–
35 s), portal (70–75 s), and equilibrium (>3 min) phases.
The acquisition parameters were 120 kVp, 440 mAs, a heli-
cal pitch of 1.375:1, 16 · 1.25 mm detector conﬁguration,
5.3 s total exposure time, 1.25 mm helical slice thickness,
and 0.625 mm reconstruction interval with a large FOV.
For image reconstruction, the axial source images were
transferred to an Advantage Workstation Volume Share 2
(GE Healthcare). Multiplanar reformatted images (MPR)
were obtained in the coronal and sagittal planes to evaluate
anatomic relations of lesions. MIP reconstruction was used
to evaluate hepatic arteries and curved planner traces the
portal vein.
3. Radiofrequency Ablation procedure: For all patients was
done under general anesthesia. RF generator used was
RITA Medical Systems, Inc., Mountain View, Calif. withentral zone and its surrounding hyperemia. (B) One month follow
arginal nodule at the periphery of the lesion. (C) The lesion after
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eter. The technique was done either under US, CT guided
or combination of both techniques according to tumor
location and accessibility. Immediately post RF ablation
MDCT was done to assess RF coverage; presence of resid-
ual and need for reablation; detection of immediate compli-
cations; assessment of marginal hyperemia and to conﬁrm a
tumor-free margin (at least 5 mm).
4. Follow up MDCT protocol was done as follows:
 1 month follow up for evaluation of residual tumor or
delayed complication.
 3 and 6 months follow up to determine any recurrence
or newly developed HCC nodules.
 One year follow up for evaluation of true technical
success.2.4. MDCT image analysis
 Ablation was considered to be complete when no enhance-
ment was seen within the ablated lesion. Peripheral
enhancement immediately post RF was considered peri-
focal reactive hyperemia.
 Nodular or irregular enhancement at the arterial phase was
considered to be viable tumor (residuals or recurrence)
according to the time of assessment.
 New HCC enhancing nodules were considered with respect
to ablated lesions.Fig. 3 (A) Large sized HCC 1 month after RF ablation showing com
effusion were detected. (B) 3 months follow up showed no enhancemen
lesion and circumferential irregular nodular marginal enhancement
chemoembolization. Post RF ablation complications were recorded including;
major complications (hemoperitoneum, bowel or gastric
perforation, pneumothorax, hemothorax, hydrothorax
and AVF) and minor complications (infection, sub capsular
hematoma and biloma).3. Results
In our study we recruited thirty patients who underwent RF
ablation for HCC nodules. They were 23 males (76.6%) and
7 females (23.3%). Their ages ranged between 54 and 64 with
mean age of 59 ± 5 years.
All patients underwent baseline pre-ablation high quality
multiphasic MDCT for assessment of site, size and number of
lesions. 24 patients (80%) had HCC nodules at the right hepatic
lobe and 6 patients (20%) at the left hepatic lobe. Regarding the
tumor size; it was ranging from 2.5 to 4.5 cm (mean 3.5 cm).
In MDCT 25 lesions were hypervascular in the arterial
phase, while 5 lesions were hypo vascular and conﬁrmed with
alpha-feto-protein.
Immediate post ablation triphasic MDCT study was
performed for all patients and reviewed immediately before
recovery from anesthesia to conﬁrm complete ablation of
the tumor. The ablated area appeared as hypo attenuation area
relative to the surrounding liver with no enhancement (29/30)
patients. One patient showed enhancing marginal nodule in the
arterial phase denoted residual tumor tissue that is reablated inplete ablation. Mild Rt. basal consolidation and minimal pleural
t. (C) and (D) 6 months follow up showed increase in the size of the
denoting local tumor recurrence which required a session of
MDCT assessment of HCC patient after radiofrequency ablation 413the same session. All patients showed bright zone around the
ablated lesions denoted reactive hyperaemia (Fig. 1) (Table 1).
MDCT follow up was done at 1, 3, 6 and 12 months. In all
our follow ups gas bubbles and the hyperemic zone disappeared
in all studies. In one month follow up nodular marginal
enhancement denoted residual tumor was seen in 2 patients
(6.6%) (Fig. 2) while hypo attenuation zone denoted good abla-
tion was seen in 28 patients (93.4%). Three months follow up
showed the hypo attenuation zone with no contrast enhance-
ment either marginal or in any site of the hepatic parenchyma
(100% of patients) conﬁrming no residual tumor or recurrence.
Six months follow up showed recurrence in one patient as
enhancing marginal nodule (3.3%) (Fig. 3) and another one
(3.3%) showed a new focus at the left hepatic lobe which is also
ablated immediately after detection (Fig. 4). One year follow
up showed enhancing marginal nodules denoted marginal
recurrence in three patients (10%) that need reablation. Mean-
ing that early good results do not assure high rate of success
(Table 2).
Multiple post RF complications were detected in our study.
They included major complications such as intra peritoneal
hemorrhage, biloma and A-V shunt that were seen in one pa-
tient for each. Minor complications also encountered are
shown in Table 3.
4. Discussion
In the last decade there was an extensive use of ultrasound sur-
veillance, in patients with hepatic cirrhosis. This made HCCFig. 4 (A) Axial CT image showing a small HCC nodule at segment I
up after RF ablation showing good ablation, no residual. (C) Six mon
newly developed enhancing small HCC nodule at segment II away frodiagnosis increasing at an early asymptomatic stage which in-
cludes Child A and B categories. Ultrasound represented a
very satisfactory diagnostic tool, approved to have high sensi-
tivity approaching 90% in detection of HCC nodules. How-
ever, its role as a follow up method after RF ablation was
not satisfactory, because it only provides morphological
assessment of the lesions with no sufﬁcient information about
tissue viability (18).
Precise assessment of post RF treatment needed a new tool
that can provide a dynamic study, assess coagulated (dead) tis-
sue and the possibility of any residual or recurrent viable tu-
mor tissues. After recent advances in the era of MDCT, now
it is considered the modality of choice to assess treatment
response for ablated hepatic focal lesions.
In our study we enrolled 30 patients with small and medium
sized HCC to evaluate the efﬁciency of high quality MDCT in
follow up of post RF ablation patients. Immediate MDCT
study showed successfully ablated lesion as hypodense area
with no contrast enhancement in the arterial phase which is be-
lieved to represent necrosis of ablated tumor tissue. Residual
viable tumor tissue was seen as enhancing irregular marginal
nodule in the arterial phase. This agreed with what described
before in many reports (12,13,17,19).
Peripheral thin rim of enhancement with uniform thickness
seen in 56.6% of our patients in immediate post RF study rep-
resented reactive hyperemia and disappear at one month fol-
low up study. This agreed with what reported by Lim et al.
(2001) who detected the same feature in 79% of his patients
(17).I with mild enhancement in the arterial phase. (B) 3 months follow
ths follow up; the ablated area with no enhancement but there is a
m ablated zone. The new lesion ablated in another setting.
Table 2 MDCT ﬁndings in follow up of 30 patients post RF ablation of HCC nodules.
MDCT ﬁndings One month Three month Six month One year
Hypo-attenuation zone denoting good ablation 28 (93%) 30 (100%) 28 (93%) 27 (90%)
Marginal enhancing nodules denoting local recurrence 2 (6.6%) 0 1 (3.3%) 3 (10%)
Newly developed enhancing nodule denoting distant spread 0 0 1 (3.3%) 0
Late complication 4 (13%) 2 (6.6%) 1 (3.3%) 1 (3.3)
Table 3 Post RF complications.
Complication Number Percent
Pleural eﬀusion 2 6.6
Rt. basal consolidation 2 6.6
Sub-capsular hematoma 2 6.6
Biloma 1 3.3
Arterio-venous shunt 1 3.3
Intraperitoneal hemorrhage 1 3.3
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(93.3%) compared with previous reports such as Lim et al.
(2001). However, we found in our study that good results in
early MDCT did not assure successful treatment. There was
no evidence of any enhancing tumor tissue in six months
follow up however, later in one year follow up we had 3
patients (10%) with enhanced tumor regrowth at the periphery
of the ablated lesions. This was concordant with previous stud-
ies such as Gazelle et al. (2000) and Lim et al. (2001) who
stated that rates of local tumor recurrence have been reported
to vary from 1.8% to 34%. This may be attributed to the
inability to identify the residual tumor within the hyperaemic
zone that often present after ablation (13,17).
This problem necessitates the use of other facilities of imag-
ing such as CT perfusion or other functional imaging such as
contrast enhanced MRI or PET CT to reduce the rate of recur-
rence in delayed follow up and increase the rate of technical
success. This agreed with Ippolito et al. (2013) who stated that
CT perfusion enables the assessment of vascularity of lesions
after RF ablation, by adding the quantitative information
about the presence of any residual vessels within viable tissue.
Also agreed with Park et al. (2008) who stated that functional
modality may be an important diagnostic method for early
detection of residual tumor tissue and local progression (20,21).
However MDCT can detect many complications after the
procedure. Two of them only were major; intraperitoneal hem-
orrhage and A-V shunt. This was considered accepted rate of
complications regarding what was reported in other studies
such as that of Livraghi et al. (2003) and Mulier et al. (2002)
where they reported that the rate of complication of RFA ran-
ged from 2.4% to 8.9%. On contrary to the study of Lim et al.
(2001) that included 40 patients and arterio-venous shunt was
detected in 10 of them (17,22,23).
5. Conclusion and recommendation
RF ablation is proved to be relatively safe, non invasive
treatment for HCC nodules. Strict MDCT follow up must be
applied for early detection of local recurrence or distant spread
that allowed complete control of the disease and improved the
technical rate of success. However, addition of other
functional imaging methods such as CT perfusion, PET CTor contrast enhanced MRI may increase the accuracy of
procedure evaluation and increase the rate of technical success.
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